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Background: Carpal tunnel syndrome (CTS) is the most common neuropathy of the upper limb and a significant
contributor to hand functional impairment and disability. Effective treatment options include conservative and
surgical interventions, however it is not possible at present to predict the outcome of treatment. The primary aim
of this study is to identify which baseline clinical factors predict a good outcome from conservative treatment
(by injection) or surgery in patients diagnosed with carpal tunnel syndrome. Secondary aims are to describe the
clinical course and progression of CTS, and to describe and predict the UK cost of CTS to the individual, National
Health Service (NHS) and society over a two year period.
Methods/Design: In this prospective observational cohort study patients presenting with clinical signs and symptoms
typical of CTS and in whom the diagnosis is confirmed by nerve conduction studies are invited to participate. Data
on putative predictive factors are collected at baseline and follow-up through patient questionnaires and include
standardised measures of symptom severity, hand function, psychological and physical health, comorbidity and
quality of life. Resource use and cost over the 2 year period such as prescribed medications, NHS and private
healthcare contacts are also collected through patient self-report at 6, 12, 18 and 24 months. The primary outcome
used to classify treatment success or failures will be a 5-point global assessment of change. Secondary outcomes
include changes in clinical symptoms, functioning, psychological health, quality of life and resource use.
A multivariable model of factors which predict outcome and cost will be developed.
Discussion: This prospective cohort study will provide important data on the clinical course and UK costs of CTS over a
two-year period and begin to identify predictive factors for treatment success from conservative and surgical interventions.Background
Carpal Tunnel Syndrome (CTS) is the commonest per-
ipheral entrapment neuropathy which causes pain, tin-
gling, numbness and weakness in the distribution of the
median nerve of the hand. It is bilateral in 55-65% of cases
[1] and is a significant contributor to impaired hand func-
tion and work disability. In the UK in 2000 the annual age
standardised rate per 100,000 was 87.8 for men and 192.8
for women [2]. There are no estimates of the cost of CTS
to UK society or the NHS, however societal costs to the
USA of patients undergoing decompression surgery were
estimated at over $2bn in 1995 [3]. More recently in 2007,* Correspondence: c.jerosch-herold@uea.ac.uk
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article, unless otherwise stated.the income loss per CTS patient over a period of 6 years
was estimated at $45,000-89,000 compared with controls
(upper extremity fracture and dermatitis) [4].
Treatment options which are supported by high qual-
ity evidence are corticosteroid injection for mild to mod-
erate symptoms [5,6] and surgical decompression in
moderate to severe cases [7]. Surgery rates in 1995 in
the UK were 71 per 100,000 [8] and rising to 90/100,000
a decade later [9]. Although steroid injection is an effect-
ive and relatively safe first line of treatment, its benefit
beyond 8 weeks has not been demonstrated [5]. A UK
study by Latinovic found that 31% of patients proceeded
to surgery within 1 year of initial presentation to their
General Practitioner [2]. A study in the Netherlands
found that only 25% of patients had a good outcome at
1 year after steroid injection [10]. Similarly, Meys et al.Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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quired surgery by 1 year. Surgical rates vary from country
to country and depend on referral criteria. The introduc-
tion of ‘low priority procedure’ thresholds by NHS trusts
in England may account for lower surgery rates in the UK
compared to the US or Europe.
The treatment algorithm currently used by most NHS
Trusts in England is to refer patients to surgery only
when symptoms are severe and disabling or when ster-
oid injections have failed. Where injection fails to resolve
symptoms, this prolongs the duration of symptoms and
associated disability as well as incurring direct and indir-
ect costs. As yet it is not possible to predict which pa-
tients will obtain long-term relief from steroid injection
and which will require surgical decompression. Longer
duration of symptoms and greater severity of symptoms
are also associated with poorer surgical outcomes al-
though the evidence seems equivocal [12].
Surgical decompression is effective in most patients,
however reported success rates vary. An analysis of pooled
results from 209 studies, representing 32,936 operations,
found that 75% of patients considered themselves im-
proved, much better or cured [13]. Misdiagnosis and surgi-
cal errors such as incomplete decompression are the most
common reasons for failure. The answer to the question of
what factors predict a good surgical outcome has so far
eluded us.
The authors of a recent systematic review of surgical
and non-surgical treatments concluded that future re-
search needed to focus on ‘prognostic studies which lead
to better patient characterisation and the identification
of predictive factors that indicate likely response to spe-
cific treatments’ [14]. Although a number of studies have
explored prognostic factors, these have been conducted
either retrospectively or in the context of randomised
trials which has limitations [15]. To date no prospective
cohort study of prognostic factors has been undertaken.
The value of high quality prognostic research is that it
leads to a better understanding of disease progression,
better targeting of effective treatments that mitigate pro-
gression and allows more reliable information about the
risk of a negative outcome to be communicated to pa-
tients [15]. A cohort study of prognostic factors would be
the first necessary step towards the development and fur-
ther external validation of clinical prediction rules. This
work would also address the need to focus on outcomes
that matter to patients as outlined in the NHS Outcomes
Framework [16] by collecting patient-reported outcomes
on one of the commonest elective surgical procedures in
the upper extremity.
Aims and objectives
The primary aim of this cohort study is to identify prog-
nostic indicators of outcome for surgical and conservativetreatment by corticosteroid injection in patients pre-
senting for nerve conduction tests with symptoms of car-
pal tunnel syndrome, managed according to current best
practice and followed up for up to 2 years.
Specific objectives are:
1) To identify baseline clinical, psychological and
sociodemographic predictors for response to
treatment by injection and surgical decompression
in patients diagnosed with CTS.
2) To describe the course and progression of CTS in treated
and untreated patients over 2 years from diagnosis.
3) To describe and identify factors that predict the cost of
CTS to the NHS and society over a period of 2 years.
4) To pilot a web-based system for routine collection
of clinical baseline and patient-reported outcomes in
patients undergoing treatment for CTS.
Methods/Design
Design
A prospective observational cohort study of patients diag-
nosed with CTS through clinical examination and history
and confirmed by nerve conduction studies. Data on puta-
tive prognostic factors and outcomes of corticosteroid in-
jection and surgery for CTS will be collected over a 2 year
period.
Study setting
In Norfolk approximately 1200 patients per annum are
referred with suspected carpal tunnel syndrome to clinical
neurophysiology at the Norfolk and Norwich University
Hospitals NHS Foundation Trust (NNUH). Nerve conduc-
tion studies (NCS) are done on both hands to confirm a
clinical diagnosis, objectively grade the severity of compres-
sion and make treatment recommendations based upon it.
Referrals come from primary care e.g. general practitioner,
community physiotherapist, and secondary care e.g. ortho-
paedics, rheumatology and plastic surgery.
Inclusion criteria
Adults aged 18 years and over who attend for NCS in the
Department of Neurophysiology and are confirmed to have
CTS of at least mild severity (grade ≥ 1 on Padua scale [17])
based on a combination of NCS results and clinical diagno-
sis, in at least one hand and for which either no treatment
is recommended at present or conservative or surgical
treatment is recommended. Patients with idiopathic as well
as secondary CTS due to diabetes or hypothyroidism will
be included.
Exclusion criteria
 Patients with unilateral CTS who have had carpal
tunnel surgery in that hand in the last 12 months.
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postpartum due to the often transient nature of
CTS.
 Serious co-morbidity e.g. malignancy, severe mental
illness and where the GP considers the patient to be
vulnerable and for whom participation would be
otherwise detrimental.
 Other symptomatic upper limb mononeuropathies,
vibration induced conditions, radiculopathy or
thoracic outlet syndrome.
 Any other sensory or motor disturbances affecting
the upper limb such as stroke, multiple sclerosis,
nerve injury.
 Unable to read or write English.
Recruitment procedure
Potentially eligible patients will be identified by the con-
sultant neurophysiologist based on the clinical history
and NCS results. The patients will be informed verbally
about the current study and given an information pack
containing an invitation to participate, a screening ques-
tionnaire and consent form. Patients will be asked to read
through these in their own time at home and a telephone
number for the study coordinator is provided if patients
have any further questions. Patients who wish to partici-
pate will be asked to complete and return the consent
form and screening questionnaire in an enclosed stamped
addressed envelope within 2 weeks. Those who do not
wish to participate will be asked to still complete the
screening questionnaire which does not require disclosure
of any personally identifiable information. Their data will
be used to compare the consenters with non-consenters
and assess external validity of the study. Those patients
returning a valid signed consent form will be contacted by
the study coordinator via the telephone who will verify
that they meet eligibility criteria and also to verify that
patients have given fully informed consent. In order to
maximise response rates a reminder letter will be sent by
the consultant neurophysiologists to all patients who were
deemed eligible and given a study invitation pack within
1 week of attendance at the department of Neurophysi-
ology. Each patient will only be enrolled into the study
once even where CTS presents bilaterally.
Care pathway
The NCS report from the Neurophysiologist will deter-
mine the severity of CTS and include treatment recom-
mendations. The clinical management of patients will be
at the discretion of the consultant clinical neurophysi-
ologist or referring clinician informed by local guidelines
for commissioning and best practice guidelines. Patients
who are eligible for the study will fall into three categories:
i) no further treatment recommended or required (watch
and wait), ii) recommended for conservative treatmentby splinting and/or corticosteroid injection; iii) recom-
mended for surgical decompression.
i) No further treatment – patients in this group are
expected to have very mild symptoms and NCS
confirming a mild compression. They either do not
require any conservative treatment or have declined
the offer of conservative treatment such as
corticosteroid injection.
ii) Conservative treatment – patients in this group are
expected to have mild to moderate CTS based on
NCS results and will be offered steroid injection and
splints.
iii)Surgical treatment – patients in this group are
expected to have moderate to severe CTS based on
NCS results and self-reported symptom severity. These
patients are likely to meet the current thresholds for
surgical referral which are: referral to secondary care if
symptoms are not resolved to patient’s satisfaction
after 6 months of conservative treatment from date of
1st consultation with physician or if neurological
deficit is present, i.e. sensory blunting or weakness of
thenar abduction (APB).
During the 2 year follow-up, patients may undergo dif-
ferent treatments depending on the course of the CTS.
For example a patient may be recommended not to have
treatment when first enrolled however 6 months later
symptom severity and associated disability may have in-
creased necessitating conservative treatment. Or a patient
may be treated with corticosteroid injection initially and
progress to surgery in the course of the 2 years. Patients
may also seek or be offered other treatments including
alternative therapies.
All types of treatments received for CTS of either
hand will be recorded by patients through 6 monthly
self-report. To assist patients in the recall of treatments
received a 6 months diary card will be issued in which
they can record date, type, dosage and out of pocket
expenditures for any treatments for CTS.
Questionnaire data
Data on putative predictive factors will be collected with a
study specific questionnaire through a combination of stan-
dardised measures and purposely designed questionnaires:
Symptom severity will be assessed with the 6-item
short form of the Boston Carpal Tunnel Questionnaire,
the CTS-6 [18].
Hand functional status will be assessed with three sub-
scales of the Michigan Hand Questionnaire (MHQ) which
capture unilateral and bilateral hand function, activities of
daily living and work performance [19].
Psychological status has been identified as a predictor
of outcome in several studies and will be measured using
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(HADs) [20].
Health-related quality of life and health utility will be
assessed by the EQ-5D-3 L (www.EuroQol.org). Results
of the EQ-5D-3 L will be converted into utilities by ap-
plying UK specific preference weights to the health pro-
files. QALYs accrued will be calculated by integrating
utility with respect to time. QALYs accrued in year two
will be discounted by 3.5%.
Comorbidity will be assessed using a self-administered
standardised Comorbidity Questionnaire developed by
Sangha et al. [21].
Additionally, at baseline other clinical and sociodemo-
graphic factors will be collected through self-report in-
cluding age, sex, ethnicity, work status and type of work,
smoking status, alcohol use, household income.
Results from NCS will be requested from the neuro-
physiologist once patients have consented and been en-
rolled into the study. Median nerve sensory nerve action
potential (amplitude and velocity) for digit III and distal
motor latency (amplitude and velocity) will be recorded.
Padua’s criteria [17,22] for classifying CTS severity accord-
ing to the neurophysiology results will be used to grade
severity from 1 to 6 (mild to extremely severe).
Resource use and cost
Patients will be asked to complete a set of resource use
questions asking about prescribed medications, primary,
secondary and tertiary NHS and private healthcare con-
tacts, alternative therapies and over the counter medi-
cines purchased and time off work due to CTS since the
last follow-up. The questionnaire completed at baseline
will pertain to resource use in the three months prior to
commencement of the study. Following completion of the
baseline questionnaire and each follow-up (except final
follow-up), patients will be issued with a ‘resource use
diary’ in the form of a card with tick-boxes and space for
notes for patients to complete over the interim time period
[23]. This will be used as an aide memoire when complet-
ing the resource use sections of the questionnaires.
To verify the patient-self-reported data, at the 2 year
follow-up the General Practitioner of a random sample
of at least 10% of patients will be contacted to confirm
numbers of primary care contacts for CTS, whether the
patient is still receiving treatment for CTS, details of
drug and dosage where corticosteroid injection has been
given, and other drugs prescribed for CTS. Records of
surgery performed will also be extracted and compared
with patient reported data.
Outcomes
The primary outcome used to classify treatment suc-
cesses and failures will be patient-reported global assess-
ment of outcome (GAO) at 2 years using a 5 pointordinal scale: worse = 1, unchanged = 2, slightly better = 3,
much better = 4, completely cured = 5. A grade of 3 or
above will be defined as treatment success. Secondary
outcomes include patient-reported clinical symptoms
(CTS-6), functioning (MHQ), psychological health HADs,
quality of life (EQ-5D) and resource use.
Data collection methods
All patients enrolled into the study will be asked to
complete a questionnaire at baseline and again at 6, 12,
18 and 24 months. Given the increasing proportion of
patients who have access to the internet it is possible to
collect these data online using secure encrypted web-
based systems which are a cost-effective alternative to
paper questionnaires. At initial enrolment patients will
be asked if they have access to the internet and given
the option to complete all follow-up questionnaires by
mail or electronically. Data entry will be via a web-based
system provided by Norwich Clinical Trials Unit Data
Management team. Any individual, whether study staff
or participant entering data online will gain access to the
website using a unique username and password. Partici-
pants will only have access to their own data. Once a
participant has confirmed the submission of data, they
will not be able to change it. The database is built using
MS SQL Server and the website and associated software
is built using MS ASP.NET. The database and website
reside on the Norwich CTU secure server at University
of East Anglia. Data from patients who opt to return
questionnaires via the post will be entered by a research
associate. On receipt of a completed online or paper
questionnaire participants will be sent a thank you card
and a diary to help them record information about treat-
ments received and out of pocket expenses incurred as a
result of the carpal tunnel syndrome for the forthcoming
6 months.
Sample size
An estimated 1200 patients are seen at the Norfolk and
Norwich University Hospital (NNUH) each year with
suspected carpal tunnel syndrome. Of these, at least 85%
(around 1020) will be confirmed as having CTS through
NCS indicating a mild or worse compression. Assuming
a recruitment rate of 75%, which is not unreasonable,
given previous experiences, we would expect to recruit
around 765 CTS subjects per annum, i.e. 1530 over the
two year recruitment period. It is estimated that around
30% (460) will go to surgery immediately and 70%
(1070) will be treated with corticosteroid injection. Of
the latter, it is expected that, by two years follow-up, two
thirds will have been referred for surgery, whereas the
remaining third (about 355) will be considered a success.
There is no standard agreed method for calculating sam-
ple sizes or statistical power for logistic regression models.
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sample size of 1070 would confer 90% statistical power,
assuming a 33% success rate, to detect an increase in
success with an odds ratio of 1.51 for an explanatory
binary variable with an even split in classification (i.e. an
equal number of subjects in each group). For an uneven
split, this odds ratio would be smaller. Should recruitment
be less than expected, a sample size of 535 (i.e. half that
expected) would confer 90% power to detect an odds ratio
of 1.79.
Analysis
The primary outcome (global assessment of outcome) will
be modelled using a binary logistic regression model. Pre-
dictors will be considered on a univariate basis and those
found to have a statistically significant effect on the out-
come (at the 10% level) will be entered simultaneously into
a multivariable model. A backwards deletion approach
based upon change in likelihood will be used to remove
those predictors with no significant independent effect. An
ordinal logistic regression model will also be considered
based upon the proportional odds assumption using the
original 5 point ordinal scale as the outcome. However, as
the assumption is often difficult to verify, this will be con-
sidered as a secondary analysis.
Secondary outcomes will be analysed in a similar fash-
ion using regression models with link functions and error
terms appropriate to the distribution of the outcome of
interest.
Cost of illness analysis
The resource use data will be used to perform a longitu-
dinal estimate of the cost of illness of carpal tunnel syn-
drome in the subject cohort over a period of two years
from the perspectives of the NHS and society (defined
as the sum of NHS and patient out of pocket costs and
morbidity-related lost productivity). The total cost of
each patient will be calculated as the sum of resource
quantities multiplied by relevant unit costs extracted
from standard NHS databases (e.g. NHS reference costs and
Unit Costs of Health and Social Care). Unit cost sources
will be from a common price year, to be determined at
time of analysis. Costs incurred in year two will be dis-
counted at 3.5% as per HM Treasury guidelines.
Regression models will be developed as described above
to predict cost over two years according to a number of
prognostic variables, e.g. symptom severity or functional
status at baseline, age, and socioeconomic status. The ana-
lysis will make appropriate adjustments to take account
of missing and censored data where necessary. Where
there are systematic differences between patient self-
reported data and primary care records, a secondary ana-
lysis will be conducted adjusting primary care cost for any
observed bias.Project timetable
Recruitment to the study began in July 2013 and is due
to be completed by July 2015. The two-year follow-up is
anticipated to be completed in July 2017.
Ethical approval
The PALMS study was approved by the East of England/
Norfolk Research Ethics Committee (REC reference 13/
EE/0106) on 22 April 2013.
Discussion
CTS is the most common nerve entrapment disorder of
the upper limb which can lead to considerable hand dis-
ability and sickness absence in those working, yet little is
known about the cost of CTS to the individual, NHS or
society. A range of effective treatment options are avail-
able including conservative and surgical interventions.
However it is not known which patients are more likely to
benefit from what treatment. This prognostic study will
provide important information about what baseline factors
may predict a good long-term response to conservative
treatment and which patients may ultimately require sur-
gery. It is an important first step in building a multivari-
able model, which can be externally validated in future
studies. The value of high quality prognostic research is
that it leads to a better understanding of disease progres-
sion, better targeting of effective treatments that mitigate
progression and allows more reliable information about
the risk of a negative outcome to be communicated to pa-
tients [15].
We were faced with a number of design issues that arose
during development of the study, not least in the choice of
outcome measures. A review of the literature was under-
taken to identify those factors which have been shown to
be predictive of outcomes for surgical and conservative
treatments. Although a number of studies have explored
predictive factors these have been conducted either retro-
spectively, are based on small sample sizes or have been
done in the context of randomised trials which has limita-
tions. Katz et al. [25] studied 241 patients enrolled in a
community based study of outcomes for CTS treatment.
78% completed follow-up at 18 months. In a bivariate ana-
lysis higher pre-operative symptom severity and functional
limitations (measured on Boston Carpal Tunnel Question-
naire [26]), lower mental health status and lower physical
health status (measured by SF-12) were associated with
worse outcome after surgery. Work-related variables asso-
ciated with a worse outcome after surgery were being in
receipt of workers’ compensation and where an attorney
was involved, heavy manual labour and those using repeti-
tive forceful exertions. Linear regression identified greater
pre-operative functional limitation, tobacco and alcohol
use, worse mental health status, prominent day pain and
bilateral symptoms as predictors of worse outcome. Those
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symptom status. A study by Meys [11] at al examined prog-
nostic factors for response to corticosteroid injection in a
prospective cohort study of 118 patients in the Netherlands.
Successful outcome was defined as no need for further
treatment within 1 year of injection. 67.4% proceeded to
surgery by 1 year. Predictors of successful outcome from
steroid injection were a lower Boston symptom severity
score, lower median nerve ultrasonic cross-sectional area
and lower median nerve swelling ratio.
Other putative factors which have been identified in
the literature include duration of symptoms, severity of
paraesthesia at night [27], constant paraesthesia and older
age [28]. Whilst these studies do not offer any definitive
answers they have been useful in identifying putative pre-
dictors which should be included in our study.
We therefore chose to measure CTS severity, hand func-
tional status, psychological status, overall health related
quality of life, co-morbidities, as well as health service
resource use and out of pocket costs.
Symptom severity in CTS is normally assessed using the
symptom severity subscale of the standardised, disease-
specific and patient-reported Levine scale [26] (also called
the CTS questionnaire or Boston Carpal Tunnel Question-
naire). It is validated for patients with CTS and has been
widely used in trials for conservative and surgical treatment
for CTS [29]. Recently a shortened version has been devel-
oped by Atroshi et al. [18] and its psychometric properties
assessed using both factor analysis and item-response the-
ory (RASCH analysis). It contains 6 items rather than 11
items. We therefore elected to use this version.
Hand functional status can be assessed using the 8-item
subscale of the Levine scale, however it has been shown
that the items are not specific enough to CTS [18] and
other measures of hand and arm disability have been devel-
oped since, including the Disabilities of the Arm, Shoulder
and Hand (DASH) [30] and Michigan Hand Questionnaire
(MHQ) [19]. A limitation of the DASH questionnaire is
that the score can be greatly affected by comorbid lower
limb disability [31] and it does not generate a separate score
for each hand. The MHQ is the only scale which measures
function for the left and right hands separately as well as
bilateral activities. The MHQ is a 57- item hand-specific
outcome questionnaire comprising 6 subscales that meas-
ure i) unilateral and bilateral hand function, ii) activities of
daily living, iii) pain, iv) work performance, v) aesthetics
and vi) patient satisfaction. The MHQ has been shown to
be responsive to change in patients undergoing surgical
treatment for CTS (effect sizes ranging from 0.6 to 0.9)
[32]. The MHQ pain subscale substantially overlaps with
the pain questions in the CTS-6 scale and the MHQ aes-
thetics subscale is not relevant in CTS. The MHQ satisfac-
tion subscale overlaps with the primary outcome measure,
the 5 point global assessment of change. We thereforeelected to use the remaining 3 subscales of the MHQ in
this study, that is, hand function, activities of daily living
and work performance.
Resource use data will be collected by self-reported
questionnaire. Such data are at risk of recall bias, [33] al-
though patients in general practice appear to be reason-
ably accurate in estimating GP contacts over a six month
period [34]. Use of a diary as an aide memoire will help
ensure fidelity of the data. However, to further verify the
patient-self-reported data, we will contact at least 10% of
patients’ GPs to confirm primary care activity as described
above. Records of surgery performed will also be extracted
and compared with patient reported data, although evi-
dence suggests that primary care records are a less than
ideal source of validation of secondary care activity [35].
Patient recall for secondary care activity is considered
fairly reliable [33].
We chose to include patients with diabetes within the
study. Patients with diabetes may or may not also have a
diabetic neuropathy. However as this is very difficult to
differentially diagnose from the CTS, it would be diffi-
cult to apply an exclusion criterion for those with diabetic
neuropathy reliably. There will also be a large proportion
of patients with diabetes and CTS but no diabetic neur-
opathy. Thus excluding those with diabetes may signifi-
cantly limit the number of patients who can be recruited,
as well as potentially affecting the generalizability of the
results. Moreover by including these patients in the ana-
lysis it will be possible to examine the effect of diabetes as
a comorbid factor on outcome.
We chose to recruit patients through clinical neuro-
physiology. This has two advantages: firstly, the diagnosis
of CTS will be made through a combination of good clin-
ical examination, history taking and NCS, therefore redu-
cing the risk of treatment failures due to misdiagnosis.
Secondly, it provides a single point of recruitment for
patients referred from primary and secondary care from a
large catchment area in Norfolk/Suffolk. Nevertheless,
although it was initially planned as a single centre study,
initial recruitment data indicates that the response rate is
lower than anticipated and further departments of neuro-
physiology within the UK will be included subject to local
research governance approval.
This prospective cohort study will provide information
on the course and cost of CTS to the individual, the health
service and society as well as identify predictive factors for
a good outcome from conservative and surgical treatment.
It may guide future development of clinical care pathways
for CTS and provide important information to service
users and providers on the likely expected outcome from
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